Mucocort AB is developing an innovative mucoadhesive "patch" for mouth ulcers (aphthous stomatitis), one of the most common oral mucosal diseases. The Chinese patent secures Mucocort's technology in one of the largest markets globally.
Mucocort AB is developing an innovative mucoadhesive "patch" for mouth ulcers (aphthous stomatitis), one of the most common oral mucosal diseases. The Chinese patent secures Mucocort's technology in one of the largest markets globally.

Press release -

Mucocort receives additional patent approval for its innovative patch technology

Mucocort AB has been granted a patent in China for its innovative product/technology, which has previously been approved under the European Patent System (EPC).
“This approval is a significant step forward in our global growth strategy”, states Jean Lycke, Project Manager at Mucocort AB.

Mucocort AB, based at Umeå Biotech Incubator, is developing an innovative mucoadhesive "patch" for mouth ulcers (aphthous stomatitis), one of the most common oral mucosal diseases.

The Chinese patent secures Mucocort’s technology in one of the world’s largest and most dynamic markets.

”We aim to be a leading global research and development company. This is a crucial component in our IPR portfolio and underscores our commitment to an ambitious IPR and market strategy”, says Jean Lycke.

This product/technology had previously received approval under the European Patent System (EPC). Mucocort is now actively working to extend its patent protection to additional countries, further bolstering the global security of its product.

Professor Thomas Hedner, Board Member at Mucocort AB, comments:

“We are very proud to have this patent approved in China, a country that is highly significant for both technological innovation and global growth. China is a strategically important market for us, and with this patent, we can effectively safeguard our technology against infringement and enhance our opportunities to form partnerships and alliances within the region”.

For more info, please contact:
Jean Lycke, project manager Mucocort AB
Telefon: 070-277 15 11
Epost: jl@emerentiagruppen.com

About Mucocort AB
Mucocort is a company within the MedTech sector, focusing on developing innovative medical solutions to improve treatment and quality of life for patients worldwide.
Through partnerships with like-minded visionaries, Mucocort AB aims to offer more effective treatments and solutions for various medical needs within mucosal treatment primarily.

Topics

Categories

Umeå Biotech Incubator (UBI) is one of Sweden’s state-of-the-art business incubators within the life sciences. We help researchers to use their data to the benefit of patients and citizens, improving their health. We support and train entrepreneurs in the fields of pharmaceuticals, diagnostics and medical engineering, and act as a bridge between academia, medicine and the business community.

Contacts

Tomas Ruuth

Tomas Ruuth

Press contact Head of PR & Communications PR & Communications 072-4024697 www.ubi.se

Related media

Download images for media use

Related content

Mucocort, business supported by Umeå Biotech Incubator, will initiate a clinical trial of their intraoral patch. The clinical trial will be conducted in collaboration with Oral Care AB and the production is managed by Aurena Laboratories AB.

Mucocort initiates clinical trial of innovative patch for aphthous stomatitis

Mucocort AB has received approval to start a clinical trial for an intraoral patch (M045A) to treat aphthous stomatitis, a condition causing mouth ulcers. The patch aims for immediate pain relief and healing promotion. The trial will be conducted in collaboration with Oral Care AB and produced by Aurena Laboratories AB in Sweden.

Mucocort secures European patent and strengthens collaboration with Aurena Laboratories

Mucocort secures European patent and strengthens collaboration with Aurena Laboratories

Swedish MedTech company Mucocort plans to launch a mucosal self-absorbing patch for pain relief in people suffering from aphthous stomatitis (mouth ulcers). The interest in Mucocort patch technology has increased after the approval of a European patent. Further, the Mucocort AB minority stakeholder Aurena Laboratories steps up with additional capital and increases its ownership.

We grow ideas that can change the world

Umeå Biotech Incubator (UBI) is one of Sweden’s state-of-the-art business incubators within the life sciences. We help researchers to use their data to the benefit of patients and citizens, improving their health. We support and train entrepreneurs in the fields of pharmaceuticals, diagnostics and medical engineering, and act as a bridge between academia, medicine and the business community.

Umeå Biotech Incubator
Umeå Biotech Incubator

Tvistevägen 48C
907 36 Umeå
Sweden

ubi.se
Umeå Biotech Incubator Enter your email address to follow Umeå Biotech Incubator

When you choose to create a user account and follow a newsroom your personal data will be used by us and the owner of the newsroom, for you to receive news and updates according to your subscription settings.

To learn more about this, please read our Privacy Policy, which applies to our use of your personal data, and our Privacy Policy for Contacts, which applies to the use of your personal data by the owner of the newsroom you follow.

Please note that our Terms of Use apply to all use of our services.

You can withdraw your consent at any time by unsubscribing or deleting your account.
Umeå Biotech Incubator Check your inbox

Email sent to __email__. Click the link there to follow Umeå Biotech Incubator.

Okay